ATLANTA–(BUSINESS WIRE)–QumulusAI (Nasdaq: QMLS), a neocloud infrastructure provider purpose-built for the AI computing era, today announced the release of a new Futurum Research report, sponsored by QumulusAI, which finds that agentic AI can increase token consumption per task by 10 to 100 times compared with a simple inference call. That increase can expose organizations using per-token services to unpredictable and rising costs as applications move into production and scale across the enter
Month: September 2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
The reverse stock split will become effective on September 28, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “CDT” on September 29, 2026, the date which has been approved by Nasdaq for the effectiveness of such split.
As of the Effective Time, every 25 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at $0.0001. Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants, as well as the applicable exercise price, and the number of shares authorized and reserved for issuance pursuant to the Company’s equity incentive plans.
The Company’s common stock will continue to trade on Nasdaq under the symbol “CDT” following the reverse stock split, with a new CUSIP number of 20678X700. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced to approximately 1,013,515. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
The Company’s transfer agent, Continental Stock Transfer & Trust Co., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding the reverse stock split, CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com
TEL AVIV, ISRAEL, Sept. 25, 2026 (GLOBE NEWSWIRE) — Arbe Robotics Ltd. (NASDAQ: ARBE), (TASE: ARBE) (“Arbe” or the “Company”), a global leader in ultra-high-resolution radar solutions, today announced that it has priced an underwritten registered direct offering of 833,334 ordinary shares at a purchase price of $0.60 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 24,166,666 ordinary shares at a purchase price of $0.5999 per share, which equals the offering price per ordinary share less the $0.0001 exercise price per share of each pre-funded warrant. The pre-funded warrants are immediately exercisable and will not expire until exercised in full. All ordinary shares and pre-funded warrants to be sold in the offering will be offered by the Company.
Arbe estimates the gross proceeds from this offering to be approximately $15 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about September 28, 2026, subject to the satisfaction of customary closing conditions. Arbe intends to use the net proceeds from this offering for working capital and general corporate purposes, including, but not limited to, scaling its operations to support growing commercial opportunities, including the recently announced selection of Arbe’s radar technology for an L3 passenger vehicle program of one of the world’s largest automotive groups and its intended expansion into the defense and counter-drone markets, as well as to potentially pursue potential strategic merger and acquisition opportunities.
Canaccord Genuity is acting as sole bookrunner for the offering.
The securities described above are being offered pursuant to a registration statement on Form F-3 (File No. 333-287805), originally filed on June 5, 2025, with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on June 13, 2025. The offering is being made only by means of a prospectus and a prospectus supplement which forms a part of the effective registration statement relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained, when available, by contacting Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Arbe Robotics Ltd.
Arbe (NASDAQ: ARBE), a global leader in ultra-high-resolution radar solutions, is redefining radar as a core sensing platform for next-generation mobility and defense. Arbe’s complete radar technology stack, from proprietary chipsets to radar systems and AI algorithms that produce perception-ready data, delivers the detail and real-time processing that demanding sensing applications require. Arbe enables OEMs, Tier-1s, and defense integrators to build more capable perception systems for passenger vehicles, robotaxis, heavy machinery, and counter-drone systems.
Headquartered in Tel Aviv, Israel, Arbe also operates offices in the United States, Germany, and China. For more information, visit https://arberobotics.com/
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected timing, completion or size of the offering, the expected gross proceeds therefrom, and the intended use of net proceeds therefrom. The words “expect,” “believe,” “estimate,” “intend,” “plan,” “anticipate,” “may,” “should,” “strategy,” “future,” “will,” “project,” “potential” and similar expressions indicate forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These risks and uncertainties include the possible delisting of the Company’s ordinary shares from Nasdaq in the event the bid price per share of the Company’s ordinary shares remains below $1.00, the effect on the Israeli economy generally and on the Company’s business resulting from the terrorism and the hostilities in Israel, including the continuing hostilities with Iran, Hezbollah and Hamas and any intensification of hostilities, and the effect of the call-up of a significant portion of its working population, including the Company’s employees, the ability of the Company to develop and market the Alerion radar system and deliver units in a timely and profitable manner, the ability of the Alerion radar system to operate as planned under wartime conditions, and the risks and uncertainties described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” and in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2026, as well as other documents filed by the Company with the SEC. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation. Information contained on, or that can be accessed through, the Company’s website or any other website or any social media is expressly not incorporated by reference into and is not a part of this press release.
Investor Relations:
Ehud Helft & Kenny Green
EK Global Investor Relations
+1 212 378 8040
In 2017, I was a young student nurse in Kenya, grappling with the stark realities of our national healthcare system. I saw families drained financially and emotionally by long-term hospital stays for their loved ones. The pain was not just in the illness but in the struggle for dignity and care. This is where Bena Care began—from a deep conviction that healthcare could be more compassionate, more accessible.
A perspective by Naom Monari, Founder & Chief Executive Officer, Bena Care
Bena Care builds a network of healthcare workers, primarily made up of nurses, physiotherapists and caregivers to deliver affordable home-nursing services and in-home therapy for chronically ill patients. Today, Bena Care has served over 16,000 patients, bringing care into homes where it’s needed most. Many of them report that this service has the potential to save them up to half of their healthcare costs. But behind these numbers are stories—a mother relieved that her son can receive dialysis closer to home, a daughter able to provide care for her mother because she was trained by our team. These are the stories that keep me going, even when the road ahead looks incredibly difficult to navigate.
- Bena Care has served over 16,000 patients, bringing care into homes where it’s needed most.
A lifeline in Boehringer Ingelheim: expanding health coverage options
In 2021, Bena Care reached a critical juncture. Running a social enterprise in healthcare is not for the faint-hearted. The financial pressures, the systemic challenges, the endless need—it can feel insurmountable. That’s when Boehringer Ingelheim’s Making More Health (MMH) entrepreneur support program came into our lives. It was more than just an opportunity, it was validation. Someone saw the potential in what we were doing and said: “Let’s make this bigger.”
Through MMH, we piloted programs that had long been part of my vision. We trained family caregivers, empowering them to provide supportive care. We launched free screenings in communities heavily burdened by diabetes and hypertension, focusing on early detection and intervention. These initiatives didn’t just work—they transformed us. Even after the program ended, these programs remained at the heart of Bena Care’s mission.
Read the whole piece on Imagine – Boehringer Ingelheim’s sustainability story hub.
In accordance with section 30 of the Capital Markets Act, Tryg A/S (“Tryg”) hereby announces that BlackRock, Inc. has notified Tryg that BlackRock, Inc. holds shares and voting rights, in accordance with section 38 of the Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Capital Markets Act and financial instruments with similar economic effect according to section 39(2)(2) of the Capital Markets Act, corresponding to more than 5% of the entire share capital and voting rights of Tryg. Please see further details in the attached notification form.
Additional information
Contact information:
- Gianandrea Roberti, Head of Financial Reporting, SVP, +45 20 18 82 67, gianandrea.roberti@tryg.dk
- Robin Hjelgaard Løfgren, Head of Investor Relations, +45 41 86 25 88, robin.loefgren@tryg.dk
Attachment
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% – January 24.09.2026 FJAN.LN IE000MDKBOB3 150,002.00 USD 4,440,016.04 29.600
LEOBENDORF, Austria–(BUSINESS WIRE)– #aestheticmedicine–Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company’s saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and ev
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells
SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG).
Long considered an incurable disease, multiple myeloma is entering a new phase in which some patients are remaining free of detectable disease for years after treatment ends. Significant advances in both myeloma therapeutic strategies and disease monitoring technologies are giving clinicians more effective ways to drive deep responses and more sensitive ways to measure them. As more patients achieve these outcomes, a clear standard for determining when a long-term response may be considered a cure is necessary. The new consensus definition establishes that standard and places sustained measurable residual disease (MRD) negativity at the center of determining whether a deep response has endured over time.
Under the consensus definition reached by global myeloma experts, a patient with newly diagnosed or relapsed disease may be considered cured after five years in complete remission without any myeloma treatment. During that period, the definition requires:
- At least four negative MRD assessments, including one at the five-year mark, with no positive result in between.
- MRD tests must use next-generation sequencing or next-generation flow at a sensitivity of 10⁻⁶, or one myeloma cell among one million cells.
- Advanced imaging, using PET/CT or diffusion-weighted whole-body MRI, must show no disease at the start and end of the period, with no positive scan in between if additional scans are performed.
These criteria illustrate that advanced disease assessment methodologies, including clonoSEQ®, will play a central role in determining which patients meet the definition of cure.
“In the world of treating multiple myeloma, we have now reached a point where we can actually cure patients. Part of that cure definition is that the patient has no measurable disease in their bone marrow,” said Dr. Jeffrey Wolf, clinical professor, Department of Medicine, University of California, San Francisco. “The ideal way of measuring that is to use the clonoSEQ Assay, which has been proven over many years to be the most reproducible way of defining residual disease in these patients.”
Establishing this consensus definition is the beginning of a new era for patients; significant ongoing research will be required to continue to expand the fraction who are cured and to better understand the probability of cure in specific patient subpopulations.
“Patients are excited to hear the cure conversation gain momentum but want to balance the hope with their lived reality,” said Jenny Ahlstrom, myeloma patient and CEO and founder, HealthTree Foundation. “Given that all myeloma is not the same, learning who can and will be cured will be one of the most important discoveries in the near future.”
“The consensus definition of cure in myeloma marks a defining moment for the patient community and a landmark achievement for the field. Together with last week’s NCCN Guidelines® update, this development clearly affirms that highly sensitive MRD assessment should be systematically integrated into routine myeloma care,” said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. “As the first and only FDA-cleared next-generation sequencing MRD test, clonoSEQ is uniquely positioned to support the level of rigor the cure definition requires, giving clinicians a precise way to measure deep responses over time and offering patients clearer insight into the outcome of their treatment.”
About clonoSEQ
clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ has been extensively studied in more than 300 peer-reviewed publications.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request.
To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision, and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Global Water UCITS ETF 24.09.2026 H2O LN IE000Q8F0M81 600,002.00 USD 11,693,733.50 19.490
HERNDON, Va., Sept. 25, 2026 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) has appointed Diane Offereins, a well-respected executive with over 35 years of experience in financial services, to the Navient board of directors, effective September 24, 2026.
“We are excited to have Diane join the Navient board and believe she is an excellent addition with her many years of experience in the financial services industry and expertise in executive compensation, information technology and cybersecurity,” said Edward Bramson, CEO and chair of the Navient board of directors.
Offereins is currently serving on the boards of Lendbuzz, Flywire and Brighthouse Financial following over 24 years with Discover Financial Services where she served as Global Chief Information Officer and completing her career as Executive Vice President, Payment Services. She graduated with a BBA in accounting from Loyola University in New Orleans.
This appointment comes after the retirement of a board member in June 2026.
About Navient
Navient (Nasdaq: NAVI) creates long-term value for customers and investors with responsible lending, flexible refinancing, trusted servicing oversight, and decades of education finance and portfolio management expertise. Through our Earnest business, we help customers confidently achieve financial success through digital financial services. Our employees thrive in a culture of belonging, where they are supported and proud to deliver meaningful outcomes. Learn more on Navient.com.
| Contact: | |
| Media: Cate Fitzgerald, 703-831-6347, catherine.fitzgerald@navient.com | |
| Investors: | Micah Andrews, 571-415-5413, micah.andrews@navient.com |
| Roger Yankoupe, 571-592-8569, roger.yankoupe@navient.com | |
